NASDAQ
EDSA

Edesa Biotech Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Edesa Biotech Inc Stock Price

Vitals

Today's Low:
$0.825
Today's High:
$0.8999
Open Price:
$0.8775
52W Low:
$0.76
52W High:
$2.81
Prev. Close:
$0.88
Volume:
39747

Company Statistics

Market Cap.:
$17.91 million
Book Value:
0.449
Revenue TTM:
$500
Operating Margin TTM:
0%
Gross Profit TTM:
$311200
Profit Margin:
0%
Return on Assets TTM:
-53.98%
Return on Equity TTM:
-101.98%

Company Profile

Edesa Biotech Inc had its IPO on 2015-11-05 under the ticker symbol EDSA.

The company operates in the Healthcare sector and Biotechnology industry. Edesa Biotech Inc has a staff strength of 16 employees.

Stock update

Shares of Edesa Biotech Inc opened at $0.88 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.83 - $0.9, and closed at $0.87.

This is a -0.68% slip from the previous day's closing price.

A total volume of 39,747 shares were traded at the close of the day’s session.

In the last one week, shares of Edesa Biotech Inc have increased by +4.05%.

Edesa Biotech Inc's Key Ratios

Edesa Biotech Inc has a market cap of $17.91 million, indicating a price to book ratio of 1.4224 and a price to sales ratio of 120477.9295.

In the last 12-months Edesa Biotech Inc’s revenue was $500 with a gross profit of $311200 and an EBITDA of $-13319690. The EBITDA ratio measures Edesa Biotech Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Edesa Biotech Inc’s operating margin was 0% while its return on assets stood at -53.98% with a return of equity of -101.98%.

In Q1, Edesa Biotech Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 99.9%.

Edesa Biotech Inc’s PE and PEG Ratio

Forward PE
0.1716
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-0.62 per share while it has a forward price to earnings multiple of 0.1716 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Edesa Biotech Inc’s profitability.

Edesa Biotech Inc stock is trading at a EV to sales ratio of 128525.384 and a EV to EBITDA ratio of -0.2229. Its price to sales ratio in the trailing 12-months stood at 120477.9295.

Edesa Biotech Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$10.67 million
Total Liabilities
$1.56 million
Operating Cash Flow
$0
Capital Expenditure
$0
Dividend Payout Ratio
0%

Edesa Biotech Inc ended 2024 with $10.67 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.67 million while shareholder equity stood at $9.00 million.

Edesa Biotech Inc ended 2024 with $0 in deferred long-term liabilities, $1.56 million in other current liabilities, 45453733.00 in common stock, $-48713719.00 in retained earnings and $0 in goodwill. Its cash balance stood at $7.47 million and cash and short-term investments were $7.47 million. The company’s total short-term debt was $65,406 while long-term debt stood at $0.

Edesa Biotech Inc’s total current assets stands at $8.13 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $50233.00 compared to accounts payable of $0 and inventory worth $0.

In 2024, Edesa Biotech Inc's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, Edesa Biotech Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.87
52-Week High
$2.81
52-Week Low
$0.76
Analyst Target Price
$11.67

Edesa Biotech Inc stock is currently trading at $0.87 per share. It touched a 52-week high of $2.81 and a 52-week low of $2.81. Analysts tracking the stock have a 12-month average target price of $11.67.

Its 50-day moving average was $0.85 and 200-day moving average was $1.12 The short ratio stood at 6.32 indicating a short percent outstanding of 0%.

Around 1921.8% of the company’s stock are held by insiders while 1629.6% are held by institutions.

Frequently Asked Questions About Edesa Biotech Inc

The stock symbol (also called stock or share ticker) of Edesa Biotech Inc is EDSA

The IPO of Edesa Biotech Inc took place on 2015-11-05

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$110.15
-4.05
-3.55%
$25.69
0.03
+0.13%
$171
0
0%
Civeo Corp (CVEO)
$20.96
1.27
+6.45%
$13.95
-0.1
-0.71%
$6.85
-0.13
-1.86%
$747.55
-3.35
-0.45%
$13.21
-0.16
-1.2%
$60.58
0.28
+0.46%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that is in Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Address

100 Spy Court, Markham, ON, Canada, L3R 5H6